Lateral epicondylitis, better known as tennis elbow, is one of the most common reasons people consider PRP, and it does not actually require tennis. In 2026, two new randomized trials and a fresh round of meta-analyses sharpened the picture: corticosteroids act faster, but PRP shows better pain and function at six months to a year. This article explains the newest evidence and what it realistically means for someone considering PRP in Honolulu.
100
patients in a 2026 RCT comparing PRP with steroid for tennis elbow
12 mo
where a 2026 trial showed PRP's greater overall improvement in pain and function
-1.60
long-term VAS difference favoring PRP in a 2025 meta-analysis
Tennis elbow is an overuse condition of the tendon that attaches the forearm muscles to the outside of the elbow. It shows up in golfers, paddlers, gardeners, painters, and office workers, not just players, and it can linger for a year or more. The tendon tissue degrades faster than it repairs, which is why it is called a tendinopathy rather than simple inflammation, and why a single quick fix rarely settles it.
A 2026 randomized trial comparing a single PRP injection with a corticosteroid injection for lateral elbow tendinopathy followed patients for a full year. The steroid relieved pain much faster: at four weeks the PRP group still averaged 47.6 points on the PRTEE questionnaire versus 14.8 for the steroid group. But by twelve months, PRP produced the greater overall improvement in pain and function. A separate 2026 randomized study of 100 patients told the same story in plain numbers: the steroid was better at one month, while PRP showed noticeably lower pain and better function at six months.
“In a 2026 randomized trial, corticosteroid relieved tennis elbow pain far faster at four weeks, while the single PRP injection produced the greater overall improvement in pain and function at twelve months.”
The trials match the pooled evidence. A 2025 meta-analysis of randomized trials comparing PRP with corticosteroids for tennis elbow found short-term pain scores favored the steroid, no meaningful difference in the intermediate months, and long-term pain scores significantly favoring PRP, with a mean difference of about 1.6 points on the 10-point VAS scale. A second 2025 review in BMC Musculoskeletal Disorders similarly found patients who received PRP had better pain and function scores than the steroid group at three and twelve months. The consistent message: PRP is not faster, but it may be more durable.
“A 2025 meta-analysis found long-term pain scores significantly favored PRP over corticosteroid for tennis elbow, with a mean difference of about 1.6 points on the 10-point VAS scale.”
The honest takeaway is not that one injection beats the other, but that they solve different problems. A steroid can buy quick relief while you rehab the tendon, but repeated steroid injections carry their own concerns. PRP needs a few weeks to show its effect and is often paired with structured loading and strengthening. For a condition that commonly lasts months, choosing an option based on durability, not just the first two weeks, is the real decision.
A note from the clinic
Tennis elbow is stubborn, but most cases improve with the right combination of diagnosis, load management, and, when appropriate, a regenerative injection. At Aloha Stem Cell in Honolulu we will help you weigh the evidence for your own elbow honestly, no pressure. Call (808) 593-2525 to start the conversation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.